Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
27 September 2021 | Story Leonie Bolleurs | Photo Supplied
Dr Frikkie Maré is serving as one of the directors of the non-profit organisation, the Agri Relief Foundation (ARF).

The agricultural sector is used to facing events of abnormal impact, including floods, droughts, veld fires, and disease outbreaks. Even if it is possible to prepare against any of these risks by taking proper measures, for instance by having a farm emergency plan in place or by securing property properly, there are times when it is not possible or practical for the modern-day South African farmer to proactively manage all the risks they are facing.

It is in times like these that the newly established body, the Agri Relief Foundation (ARF), provides an invaluable service to the agricultural sector. 

Dr Frikkie Maré, Senior Lecturer in the Department of Agricultural Economics at the University of the Free State (UFS), is one of the directors of this non-profit organisation, which focuses on assisting agricultural producers in need. 

This initiative is the brainchild of a number of businesses in the agricultural sector.

He says although there are many institutions in South Africa assisting farmers, most of the current initiatives are geared towards large-scale disasters, such as severe droughts, floods, unpreventable pests and diseases, and veld fires that affect many producers.  

Benefiting the wider society

According to Dr Maré, the ARF will focus on helping individual agricultural producers who are in need; both financially and otherwise.  This may include elements such as the loss of grazing due to brown locust, assistance after a farm attack or murder to ensure the day-to-day running of the farm, and localised natural disasters such as floods, hail, severe cold, or fire.

The group of directors plays a key role in screening the applications for assistance and deciding, based on merit and the availability of resources, who they can assist.

Besides the direct benefit to the farmer, this initiative also adds value to the wider society. “When the sustainability of an agricultural producer is under threat, it also threatens the livelihoods of his/her workers and their families, the rural economy of the nearest town where they purchase production inputs and general groceries, as well as society at large, as less food and/or fibre will be produced.  The assistance of the ARF will therefore ripple out to a much larger level than only the agricultural producer,” explains Dr Maré. 

A learning experience

There is also a benefit for the university. In the classroom, Dr Maré will be able to share any knowledge he is gaining in this process with his students. “Agricultural Economics is fundamentally about ensuring the long-term sustainability of agricultural production through concepts, including but not limited to, production economics, natural resource economics, agricultural management, and marketing.  My involvement in the ARF will provide examples of what can go wrong in terms of primary production that threatens the sustainability of the enterprise and what can be done to assist,” he says. 

Any business or individual can contribute to this noble cause. Financial contributions as well as physical products such as transport, fuel, animal feed, and legal services are welcome. 

Dr Maré says they have already received contributions from companies such as Zoetis (animal health), which sponsor a part of their profit from certain products to the foundation on a continuous basis. Lavendula (animal feed) also sponsored the proceeds of a farmers’ information day.

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept